Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Non Operating Income (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Non Operating Income for 12 consecutive years, with -$11.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income fell 131.81% year-over-year to -$11.4 million, compared with a TTM value of -$66.7 million through Sep 2025, down 220.44%, and an annual FY2024 reading of -$5000.0, up 88.1% over the prior year.
  • Non Operating Income was -$11.4 million for Q3 2025 at Avalo Therapeutics, down from -$1.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $108.0 million in Q2 2024 and bottomed at -$88.5 million in Q1 2024.
  • Average Non Operating Income over 5 years is -$824222.2, with a median of -$135000.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 211182.35% in 2024, while the deepest fall reached 340346.15% in 2024.
  • Year by year, Non Operating Income stood at -$2.4 million in 2021, then skyrocketed by 234.71% to $3.2 million in 2022, then crashed by 100.53% to -$17000.0 in 2023, then crashed by 325888.24% to -$55.4 million in 2024, then surged by 79.4% to -$11.4 million in 2025.
  • Business Quant data shows Non Operating Income for AVTX at -$11.4 million in Q3 2025, -$1.4 million in Q2 2025, and $1.5 million in Q1 2025.